Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on October 7, 2021. The report discloses a material event under Item 8.01 regarding the advancement of the company's clinical development program.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical milestone and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the initiation of patient dosing in a Phase 1/2 clinical study for GTX-102, an investigational treatment for Angelman syndrome. As of the report date, the first patient has been dosed, with three additional patients enrolled and scheduled to begin dosing.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) issued jointly with GeneTx Biotherapeutics LLC. The document does not contain specific financial guidance, management commentary on future performance, or a detailed discussion of risks and contingencies beyond the context of the clinical trial initiation.
Investor Verification Checklist
- Verify the full details of the Phase 1/2 study for GTX-102 in the attached press release (Exhibit 99.1).
- Confirm the partnership terms and roles between Ultragenyx and GeneTx Biotherapeutics LLC regarding this trial.
- Review subsequent filings for updates on patient enrollment and safety data from the trial.
- Check the company's most recent 10-Q or 10-K for current financial position and cash runway, as this 8-K does not include financial data.